Company news
Altimmune, Inc. news in 2020
Altimmune, Inc.'s news releases, calls and decks from 2020, newest first.
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
December 29, 2020
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
December 22, 2020
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
December 7, 2020
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
November 24, 2020
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
November 9, 2020
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
November 8, 2020
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
November 2, 2020
Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate
October 11, 2020
Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH
August 31, 2020
Altimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress™ 2020
August 25, 2020
Altimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID™
August 24, 2020
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
August 10, 2020
Altimmune to Announce Second Quarter 2020 Financial Results on August 12
August 4, 2020
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19
July 21, 2020
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option
July 15, 2020
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
July 12, 2020
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
July 12, 2020
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID™
July 8, 2020
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
June 29, 2020
Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19
June 28, 2020
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B
June 21, 2020
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
May 31, 2020
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
May 12, 2020
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors
May 11, 2020
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
March 29, 2020
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update
March 26, 2020
Altimmune to Announce Year End 2019 Financial Results on March 27
March 24, 2020
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
February 27, 2020
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
January 22, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (June 2020)
Investor deck · 10 slides · June 2020